Mechanisms and assessment of statin-related muscular adverse effects.
about
A Genomic DNA Reporter Screen Identifies Squalene Synthase Inhibitors That Act Cooperatively with Statins to Upregulate the Low-Density Lipoprotein ReceptorLovastatin-Mediated Changes in Human Tendon CellsA Peculiar Formula of Essential Amino Acids Prevents Rosuvastatin Myopathy in Mice.Colchicine triggered severe rhabdomyolysis after long-term low-dose simvastatin therapy: a case reportAssociation between infection and severe drug adverse reactions: an analysis using data from the Japanese Adverse Drug Event Report database.The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy.Histopathologic and Biochemical Evidence for Mitochondrial Disease Among 279 Patients with Severe Statin Myopathy.Rare variants in known and novel candidate genes predisposing to statin-associated myopathy.Fatal Statin-Induced Rhabdomyolysis by Possible Interaction with Palbociclib.Diagnostic confounders of chronic widespread pain: not always fibromyalgia.Genetic variation in human drug-related genes.Genetic and Clinical Factors Are Associated With Statin-Related Myotoxicity of Moderate Severity: A Case-Control Study.Statin therapy exacerbates alcohol-induced constriction of cerebral arteries via modulation of ethanol-induced BK channel inhibition in vascular smooth muscle.Statin-associated muscle symptoms: position paper from the Luso-Latin American Consortium.[Statin intolerance and associated muscular dysfunctions].Acute Onset Significant Muscle Weakness in a Patient Awaiting Liver Transplantation: Look for Statins.
P2860
Q33724316-1E255BDB-4BAD-4B55-A7B9-83FE81A31502Q36799885-3195FE0E-03B7-4A87-85BB-F628D3F34569Q37341027-D51A64B2-74D5-4E42-90A2-BD179D6CA9E7Q37555163-CE90E406-F697-457A-9A30-AE3D0433C4BEQ38613096-C83C1E36-6D4D-4688-8571-FA7875485A4FQ38793280-983BDD8E-6A67-491F-BA8B-21090CAC72BFQ39166726-79C163C3-6240-4AEE-AE46-BCC7C1AA7852Q40703907-453DE1FB-D1A8-4086-A441-74BCCB8EAD33Q41024017-19C7931B-1201-49A4-A51C-1E8698E23C9FQ47552826-B0832E10-2559-46E7-84B9-5135D6C72ADEQ47564586-6C9A2D81-C43E-4E28-AEC3-627F7C4FED8EQ47676842-CB5BBFA5-DAEA-46C9-BA0F-0A5764B4D149Q47865448-506B5790-FE69-4698-B6EA-A95F4FF14FA8Q51752364-E8480C82-92CE-4A74-96B1-A94613C4AFACQ53649484-682D1FB4-8E52-463B-A10C-CE50712A372CQ54067585-E798684A-E0C6-491F-911E-3304E1702CC9
P2860
Mechanisms and assessment of statin-related muscular adverse effects.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Mechanisms and assessment of statin-related muscular adverse effects.
@ast
Mechanisms and assessment of statin-related muscular adverse effects.
@en
Mechanisms and assessment of statin-related muscular adverse effects.
@nl
type
label
Mechanisms and assessment of statin-related muscular adverse effects.
@ast
Mechanisms and assessment of statin-related muscular adverse effects.
@en
Mechanisms and assessment of statin-related muscular adverse effects.
@nl
prefLabel
Mechanisms and assessment of statin-related muscular adverse effects.
@ast
Mechanisms and assessment of statin-related muscular adverse effects.
@en
Mechanisms and assessment of statin-related muscular adverse effects.
@nl
P2093
P2860
P356
P1476
Mechanisms and assessment of statin-related muscular adverse effects.
@en
P2093
Dirk Moßhammer
Klaus Mörike
Matthias Schwab
P2860
P304
P356
10.1111/BCP.12360
P407
P577
2014-09-01T00:00:00Z